CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) will present at the 30th
Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2012 at
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time at The Westin St.
Francis in San Francisco. The presentation will be followed by a
question and answer session that will begin at approximately 2:00 p.m.
Pacific Time / 5:00 p.m. Eastern Time.
A live webcast of both the presentation and the question and answer
session will be accessible through the Investors section of Ironwood's
website at www.ironwoodpharma.com.
To access the webcasts, please log on to the Ironwood website
approximately 15 minutes prior to the start time to ensure adequate time
for any software downloads that may be required. A replay of each
webcast will be available on Ironwood's website for 14 days following
the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial
pharmaceutical company dedicated to the art and science of great
drugmaking. Linaclotide, Ironwood's GC-C agonist, is an investigational
drug for the treatment of irritable bowel syndrome with constipation
(IBS-C) and chronic constipation (CC). The efficacy portion of
linaclotide's development program has been completed and supports the
recently submitted NDA for both indications, as well as the MAA
submission in Europe for the IBS-C indication. Ironwood also has a
growing pipeline of additional drug candidates in earlier stages of
development. Ironwood is located in Cambridge, Mass. To learn more,
visit www.ironwoodpharma.com.
Ironwood Pharmaceuticals
Susan Brady, 617-621-8304
Corporate
Communications
sbrady@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
News Provided by Acquire Media